GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Co Ltd (ROCO:6892) » Definitions » Equity-to-Asset

Taiwan Bio Therapeutics Co (ROCO:6892) Equity-to-Asset : 0.65 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Taiwan Bio Therapeutics Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$613.29 Mil. Taiwan Bio Therapeutics Co's Total Assets for the quarter that ended in Dec. 2023 was NT$941.76 Mil. Therefore, Taiwan Bio Therapeutics Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.65.

The historical rank and industry rank for Taiwan Bio Therapeutics Co's Equity-to-Asset or its related term are showing as below:

ROCO:6892' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.34   Med: 0.61   Max: 0.82
Current: 0.65

During the past 5 years, the highest Equity to Asset Ratio of Taiwan Bio Therapeutics Co was 0.82. The lowest was 0.34. And the median was 0.61.

ROCO:6892's Equity-to-Asset is ranked worse than
51.76% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6892: 0.65

Taiwan Bio Therapeutics Co Equity-to-Asset Historical Data

The historical data trend for Taiwan Bio Therapeutics Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Co Equity-to-Asset Chart

Taiwan Bio Therapeutics Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
0.82 0.34 0.44 0.61 0.65

Taiwan Bio Therapeutics Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial 0.44 0.65 0.61 0.67 0.65

Competitive Comparison of Taiwan Bio Therapeutics Co's Equity-to-Asset

For the Biotechnology subindustry, Taiwan Bio Therapeutics Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Bio Therapeutics Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics Co's Equity-to-Asset falls into.



Taiwan Bio Therapeutics Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Taiwan Bio Therapeutics Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=613.291/941.761
=0.65

Taiwan Bio Therapeutics Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=613.291/941.761
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Taiwan Bio Therapeutics Co  (ROCO:6892) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Taiwan Bio Therapeutics Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Co (ROCO:6892) Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Lane 120, Hu Road, Section 1, 6th Floor, Neihu District, Taipei, TWN
Taiwan Bio Therapeutics Co Ltd is a regenerative medicine company specializing in the development of new cell medicines. It provides cell product process development and foundry (CDMO/CMO) services.

Taiwan Bio Therapeutics Co (ROCO:6892) Headlines

No Headlines